Avalo Therapeutics, Inc. held its 2026 annual meeting of stockholders, where stockholders approved the Second Amended and Restated 2016 Employee Stock Purchase Plan (A&R 2016 ESPP) and elected seven board nominees. Additionally, stockholders also ratified the following: Ernst & Young LLP as the company's independent registered public accounting firm for the fiscal year 2026.
